<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03061201</url>
  </required_header>
  <id_info>
    <org_study_id>SB-525-1603</org_study_id>
    <secondary_id>C3731001</secondary_id>
    <nct_id>NCT03061201</nct_id>
  </id_info>
  <brief_title>A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A</brief_title>
  <official_title>A PHASE 1/2, OPEN-LABEL, ADAPTIVE, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF SB-525 (PF-07055480) (RECOMBINANT AAV2/6 HUMAN FACTOR 8 GENE THERAPY) IN ADULT SUBJECTS WITH SEVERE HEMOPHILIA A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability and time-course profile of&#xD;
      FVIII activity after dosing with SB-525 (PF-07055480)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed clinical study uses a recombinant adeno-associated virus 2/6 (AAV2/6) vector&#xD;
      encoding the cDNA for the B-domain deleted human F8 (hF8). The secreted FVIII has the same&#xD;
      amino acid sequence as approved recombinant anti hemophilic factors (Refacto® and Xyntha®).&#xD;
      The SB-525 (PF-07055480) vector encodes a liver-specific promotor module and AAV2/6 exhibits&#xD;
      liver tropism, thus providing the potential for long-term hepatic production of FVIII in&#xD;
      hemophilia A subjects.&#xD;
&#xD;
      The constant production of FVIII after a single SB-525 (PF-07055480) administration may&#xD;
      provide potential benefit in durable protection against bleeding and the complications&#xD;
      thereof without lifelong repetitive IV factor replacement administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Anticipated">July 23, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose selection based on safety and kinetics of circulating FVIII levels observed in previously dosed participants.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>Up to 5 years after SB-525 (PF-07055480) infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in circulating FVIII activity</measure>
    <time_frame>Up to 5 years after SB-525 (PF-07055480) infusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Sequential dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB-525 (PF-07055480) is administered as a single infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-525 (PF-07055480)</intervention_name>
    <description>Single dose of investigational product SB-525 (PF-07055480)</description>
    <arm_group_label>Sequential dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male ≥18 years of age&#xD;
&#xD;
          -  Severe hemophilia A (past evidence of circulating FVIII activity of &lt; 1% normal)&#xD;
&#xD;
          -  Treated or exposed to FVIII concentrates or cryoprecipitate for at least 150 exposure&#xD;
             days&#xD;
&#xD;
          -  ≥12 bleeding episodes if receiving on-demand therapy over the preceding 12 months&#xD;
&#xD;
          -  Agree to use double barrier contraceptive until at least 3 consecutive semen samples&#xD;
             are negative for AAV 2/6 after SB-525 infusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of neutralizing antibodies&#xD;
&#xD;
          -  Current inhibitor, or history of FVIII inhibitor (except for transient low titer&#xD;
             inhibitor detected in childhood)&#xD;
&#xD;
          -  History of hypersensitivity response to FVIII&#xD;
&#xD;
          -  History of Hepatitis B or HIV-1/2 infection&#xD;
&#xD;
          -  History of Hepatitis C, unless viral assays in two samples, collected at least 6&#xD;
             months apart, are negative&#xD;
&#xD;
          -  Evidence of any bleeding disorder in addition to hemophilia A&#xD;
&#xD;
          -  Markers of hepatic inflammation or overt or occult cirrhosis&#xD;
&#xD;
          -  History of chronic renal disease or creatinine ≥ 1.5 mg/dL&#xD;
&#xD;
          -  Presence of liver mass on magnetic resonance imaging (MRI), or, positive alpha&#xD;
             fetoprotein&#xD;
&#xD;
          -  Presence of &gt; grade 2 liver fibrosis on elastography for subjects with history of&#xD;
             treated Hepatitis C or suspicion of chronic liver disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midtown Ambulatory Care Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Ambulatory Care Clinic</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis CTSC Clinical Research Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Hemophilia Treatment Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Investigational Drug Services Pharmacy</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco - Investigational Drug Service (IDS) Pharmacy</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco - Outpatient Hematology Clinic</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco -Moffitt Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF Health Morsani Center For Advanced Healthcare</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemophilia Center of Western PA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Montefiore Clinical and Translational Research Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC, Investigational Drug Service</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Hemostasis-Thrombosis Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bloodworks NW</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=SB-525-1603</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

